CD274 and ovarian carcinoma: ,39 In the first-line treatment setting for ovarian cancer, avelumab (anti–PD-L1 antibody) showed no PFS benefits vs. placebo either in combination with chemotherapy or as a maintenance treatment in the randomized, controlled, phase 3 JAVELIN Ovarian 100 trial, which was eventually stopped for crossing the prespecified futility boundaries.40